Featured Content

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental Research

Experimental research may provide a blue print for the treatment of many types of cancer.

Janus Kinase Inhibitors for the Treatment of Myelofibrosis

The identification of driver mutations in myelofibrosis has helped cement understanding of the pathophysiology of the disease and has kick-started the development of targeted therapies.

More Features>>>

Hematologic Cancers Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs